Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sunitinib rechallenge in metastatic renal cell carcinoma
NL-OMON41227Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in renal cell carcinoma (RCC) and kidney cancer, sponsored by Vrije University Medical Center. Primary endpoint: Progression-free rate at 3 months. Started Apr 2013; status: active, not recruiting.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)kidney cancer
Beyond the preview
Go deeper on NL-OMON41227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41227.